Skip to main content

International Journal of Clinical Oncology

Ausgabe 1/2025

Inhalt (16 Artikel)

Electronic patient-reported outcomes as digital therapeutics for patients with cancer: a narrative review of current practices and future directions

  • Open Access
  • JSCO Board of Directors Series

Ken Yamaguchi, Nozomi Higashiyama, Maki Umemiya, Yoshihide Inayama, Ayami Koike, Akihiko Ueda, Rin Mizuno, Mana Taki, Koji Yamanoi, Ryusuke Murakami, Junzo Hamanishi, Masaki Mandai

Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology

  • Special Article

Kazuhisa Nakashima, Saki Harashima, Rena Kaneko, Ryuhei Tanaka, Masakazu Abe, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K. Imamura, Ayako Okuyama, Keiko Ozawa, Yong-il Kim, Eriko Satomi, Masayuki Takeda, Takako Eguchi Nakajima, Naoki Nakamura, Junichi Nishimura, Mayumi Noda, Kazumi Hayashi, Takahiro Higashi, Narikazu Boku, Koji Matsumoto, Yoko Matsumoto, Kenji Okita, Nobuyuki Yamamoto, Kenjiro Aogi, Hidenori Sasaki

Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology

  • Special Article

Michiyasu Murakami, Yoshiharu Miyata, Kazuhisa Nakashima, Masakazu Abe, Junichi Nishimura, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K. Imamura, Ayako Okuyama, Keiko Ozawa, Yong-il Kim, Hidenori Sasaki, Eriko Satomi, Masayuki Takeda, Ryuhei Tanaka, Naoki Nakamura, Mayumi Noda, Kazumi Hayashi, Takahiro Higashi, Narikazu Boku, Koji Matsumoto, Yoko Matsumoto, Kenji Okita, Nobuyuki Yamamoto, Kenjiro Aogi, Takako Eguchi Nakajima

Is it feasible to prolong the flushing interval for totally implantable venous access devices (TIVADs)? A systematic review and meta-analysis

  • Review Article

Lei Liu, Junli Liang, Zhanlun Liu, Yinghui Jin, Cuicui Ma, Xiaoyan Zhao, Mingyi Qin, Jinwei Wei, Xinsheng Li, Yanli Xie, Fengxia Liu, Laiyou Li, Jianxin Wang

Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection

  • Open Access
  • Original Article

Masayuki Kanamori, Ichiyo Shibahara, Yoshiteru Shimoda, Yukinori Akiyama, Takaaki Beppu, Shigeo Ohba, Toshiyuki Enomoto, Takahiro Ono, Yuta Mitobe, Mitsuto Hanihara, Yohei Mineharu, Joji Ishida, Kenichiro Asano, Yasuyuki Yoshida, Manabu Natsumeda, Sadahiro Nomura, Tatsuya Abe, Hajime Yonezawa, Ryuichi Katakura, Soichiro Shibui, Toshihiko Kuroiwa, Hiroyoshi Suzuki, Hidehiro Takei, Haruo Matsushita, Ryuta Saito, Yoshiki Arakawa, Yukihiko Sonoda, Yuichi Hirose, Toshihiro Kumabe, Takuhiro Yamaguchi, Hidenori Endo, Teiji Tominaga

Clinical significance of CD155 expression in surgically resected lung squamous cell carcinoma

  • Original Article

Taichi Nagano, Kazuki Takada, Asato Hashinokuchi, Kyoto Matsudo, Fumihiko Kinoshita, Takaki Akamine, Mikihiro Kohno, Mototsugu Shimokawa, Tomoyoshi Takenaka, Yoshinao Oda, Tomoharu Yoshizumi

Safety and pharmacokinetics of vepdegestrant in Japanese patients with ER+ advanced breast cancer: a phase 1 study

  • Open Access
  • Original Article

Hiroji Iwata, Yoichi Naito, Masaya Hattori, Akiyo Yoshimura, Kan Yonemori, Mana Aizawa, Yuko Mori, Junichiro Yoshimitsu, Yoshiko Umeyama, Toru Mukohara

Influence of major hepatectomy on gemcitabine-based chemotherapy for recurrent biliary tract cancer after surgery: a subgroup analysis of JCOG1113

  • Original Article

Tatsuya Okuno, Chigusa Morizane, Junki Mizusawa, Hiroaki Yanagimoto, Satoshi Kobayashi, Hiroshi Imaoka, Takeshi Terashima, Hisato Kawakami, Yusuke Sano, Takuji Okusaka, Masafumi Ikeda, Masato Ozaka, Haruo Miwa, Akiko Todaka, Satoshi Shimizu, Nobumasa Mizuno, Mitsugu Sekimoto, Keiji Sano, Kazutoshi Tobimatsu, Akio Katanuma, Kunihito Gotoh, Hironori Yamaguchi, Hiroshi Ishii, Junji Furuse, Makoto Ueno

Prognostic impact of aspirin in patients with hepatocellular carcinoma after liver resection: propensity-score-matched analysis

  • Original Article

Takashi Matsumoto, Yuki Kitano, Katsunori Imai, Daisuke Ogawa, Shinsei Yumoto, Toru Takematsu, Yuta Shiraishi, Rumi Itoyama, Shigeki Nakagawa, Kosuke Mima, Hirohisa Okabe, Hidetoshi Nitta, Hiromitsu Hayashi, Hideo Baba

Real-world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective study

  • Open Access
  • Original Article

Taigo Kato, Junya Furukawa, Nobuyuki Hinata, Kosuke Ueda, Isao Hara, Fumiya Hongo, Ryuichi Mizuno, Teppei Okamoto, Hiroshi Okuno, Takayuki Ito, Masahiro Kajita, Mototsugu Oya, Yoshihiko Tomita, Nobuo Shinohara, Masatoshi Eto, Hirotsugu Uemura

Effect of extending the period from oral administration of 5-aminolevulinic acid hydrochloride to photodynamic diagnosis during transurethral resection for non-muscle invasive bladder cancer on diagnostic accuracy and safety: a single-arm multicenter phase III trial

  • Open Access
  • Original Article

Rikiya Taoka, Hideo Fukuhara, Makito Miyake, Keita Kobayashi, Atsushi Ikeda, Kent Kanao, Yoshinobu Komai, Ryo Fujiwara, Yusuke Sato, Mikio Sugimoto, Toyonori Tsuzuki, Kiyohide Fujimoto, Keiji Inoue, Mototsugu Oya

Correction to: Effect of extending the period from oral administration of 5-aminolevulinic acid hydrochloride to photodynamic diagnosis during transurethral resection for non-muscle invasive bladder cancer on diagnostic accuracy and safety: a single-arm multicenter phase III trial

  • Open Access
  • Correction

Rikiya Taoka, Hideo Fukuhara, Makito Miyake, Keita Kobayashi, Atsushi Ikeda, Kent Kanao, Yoshinobu Komai, Ryo Fujiwara, Yusuke Sato, Mikio Sugimoto, Toyonori Tsuzuki, Kiyohide Fujimoto, Keiji Inoue, Mototsugu Oya

Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium

  • Original Article

Taizo Uchimoto, Kengo Iwatsuki, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Masanobu Saruta, Saizo Fujimoto, Takafumi Minami, Yutaka Yamamoto, Shogo Yamazaki, Tomoaki Takai, Moritoshi Sakamoto, Yuki Nakajima, Kazuki Nishimura, Ryoichi Maenosono, Takuya Tsujino, Ko Nakamura, Tatsuo Fukushima, Kyosuke Nishio, Yuki Yoshikawa, Shutaro Yamamoto, Kosuke Iwatani, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki, Kiyoshi Takahara, Teruo Inamoto, Kazutoshi Fujita, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Haruhito Azuma

Predictive factors of immediate continence after conventional robot-assisted radical prostatectomy: a single-institution retrospective study

  • Original Article

Yu Ozawa, Shin Koike, Keisuke Aoki, Keita Okamoto, Kei Ushijima, Toshiaki Kayaba, Sunao Nohara, Masumi Yamada, Yu Odagaki, Hideo Sakamoto, Kunihiko Yoshioka

Lymphadenectomy and chemotherapy are effective treatments for patients with 2023 international federation of gynecology and obstetrics stage IIC-high risk endometrial cancer in Japan

  • Open Access
  • Original Article

Yoshinori Tani, Keiichiro Nakamura, Masae Yorimitsu, Noriko Seki, Mie Nakanishi, Hironori Itou, Miyuki Shimizu, Dan Yamamoto, Etsuko Takahara, Hisashi Masuyama

Treatment selection and influencing factors for chronic lymphocytic leukemia: a physician survey in Japan

  • Open Access
  • Original Article

Junichiro Yuda, Chaochen Wang, Tomoko Terasawa, Masaomi Tajimi, Satoshi Osaga, Moemi Miura, Shori Takaoka, Yoshinori Tanizawa

Neu im Fachgebiet Onkologie

Nierenzellkarzinom: Daten zur Lebensqualität unter HIF-Inhibition vorgelegt

Seit wenigen Wochen ist mit Belzutifan eine neue Wirkstoffklasse beim fortgeschrittenen klarzelligen Nierenzellkarzinom in der EU zugelassen. Frisch publizierte Ergebnisse zur Lebensqualität erweitern jetzt die Datenbasis zur Risiko-Nutzen-Bewertung für den HIF-2α-Inhibitor.

Warum genderspezifische Medizin notwendig ist 

Laut Zahlen der WHO aus dem Jahr 2024 sterben zwei Frauen pro Minute an Krankheiten, die mit geschlechtsspezifischen Faktoren zusammenhängen. Außerdem wirken Medikamente bei ihnen oft anders als bei Männern. Zeit für ein genderspezifisches Denken in der Medizin.

Nach Vollremission bei Ösophagus-Ca. – Operation erstmal aussetzen?

Studienziel erreicht, dennoch viele Fragen offen. So lassen sich die Ergebnisse der SANO-Studie zur Active-Surveillance versus sofortigen Ösophagektomie nach neoadjuvanter Komplettremission zusammenfassen. Interessant sind die Daten so oder so.

Ältere Patientinnen mit Mammakarzinom – ist weniger mehr?

Etwa 40 % der Frauen mit Mammakarzinom in Deutschland erkranken nach dem 70. Lebensjahr. Dennoch sind ältere Patientinnen in klinischen Studien häufig unterrepräsentiert. Wie können Betroffene optimal behandelt werden, ohne sie zu übertherapieren oder ihnen durch eine Untertherapie Chancen zu nehmen?  

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.